Breast Cancer Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Breast Cancer Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028


Market Overview:

The global breast cancer liquid biopsy market size reached US$ 110.7 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 326.2 Million by 2028, exhibiting a growth rate (CAGR) of 17.81% during 2023-2028.

Breast cancer liquid biopsy refers to a non-invasive medical procedure that utilizes blood as a sample for the identification of tumor markers. It assists in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that help clinicians in choosing the best course of action at the right time. Some of the common biomarkers that are used in this process include circulating tumor cells (CTC), extracellular vesicles, circulating tumor DNA, etc. Breast cancer liquid biopsy offers several benefits, including minimal invasiveness, characterization of new lesions, drug and therapeutic target identifications for cancer treatment, etc.

Breast Cancer Liquid Biopsy Market Trends:



The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth. Moreover, various global organizations are conducting awareness campaigns to educate individuals about breast health and cancer diagnostic measures. This, in confluence with the increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures, is creating a positive outlook for the market. Apart from this, numerous manufacturers are making significant investments in the introduction of advanced biopsy techniques that enables the enhancement of several aspects of breast cancer management, such as prediction of prognosis, early diagnosis of relapse, serial sampling, efficient longitudinal monitoring of disease progress and response to treatment, etc. Furthermore, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product services, circulating biomarker and end user.

Breakup by Product Services:

Reagent Kits
Instruments
Services

Breakup by Circulating Biomarker:

Circulating Tumor Cells (CTCs)
Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Others

Breakup by End User:

Reference Laboratories
Hospitals and Physician Laboratories
Others

Breakup by Region:

North America

United States
Canada

Asia-Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others

Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others

Latin America

Brazil
Mexico
Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation).

Key Questions Answered in This Report:

What was the size of the global breast cancer liquid biopsy market in 2022?

What is the expected growth rate of the global breast cancer liquid biopsy market during 2023-2028?

What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?

What are the key factors driving the global breast cancer liquid biopsy market?

What is the breakup of the global breast cancer liquid biopsy market based on the product services?

What are the key regions in the global breast cancer liquid biopsy market?

Who are the key players/companies in the global breast cancer liquid biopsy market?


1 Preface
2 Scope and Methodology
  2.1 Objectives of the Study
  2.2 Stakeholders
  2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
  2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
  2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
  4.1 Overview
  4.2 Key Industry Trends
5 Global Breast Cancer Liquid Biopsy Market
  5.1 Market Overview
  5.2 Market Performance
  5.3 Impact of COVID-19
  5.4 Market Forecast
6 Market Breakup by Product Services
  6.1 Reagent Kits
6.1.1 Market Trends
6.1.2 Market Forecast
  6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast
  6.3 Services
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Circulating Biomarker
  7.1 Circulating Tumor Cells (CTCs)
7.1.1 Market Trends
7.1.2 Market Forecast
  7.2 Cell-Free DNA (cfDNA)
7.2.1 Market Trends
7.2.2 Market Forecast
  7.3 Extracellular Vesicles (EVs)
7.3.1 Market Trends
7.3.2 Market Forecast
  7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End User
  8.1 Reference Laboratories 
8.1.1 Market Trends
8.1.2 Market Forecast
  8.2 Hospitals and Physician Laboratories
8.2.1 Market Trends
8.2.2 Market Forecast
  8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
  9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
  9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
  9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
  9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
  9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
  10.1 Overview
  10.2 Strengths
  10.3 Weaknesses
  10.4 Opportunities
  10.5 Threats
11  Value Chain Analysis
12  Porters Five Forces Analysis
  12.1 Overview
  12.2 Bargaining Power of Buyers
  12.3 Bargaining Power of Suppliers
  12.4 Degree of Competition
  12.5 Threat of New Entrants
  12.6 Threat of Substitutes
13  Price Analysis
14  Competitive Landscape
  14.1 Market Structure
  14.2 Key Players
  14.3 Profiles of Key Players
14.3.1 Biocept Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Bio-Rad Laboratories Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 F. Hoffmann-La Roche AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Fluxion Biosciences Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Guardant Health Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Illumina Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Menarini Silicon Biosystems (The Menarini Group)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 NeoGenomics Laboratories Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Qiagen
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Sysmex Europe SE (Sysmex Corporation)
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings